Cornier, who has received compensation from Novo Nordisk for serving as a consultant, echoed some of Banks concerns
The drug has established a strong therapeutic foundation with semaglutide 2.4 mg approved for chronic weight management in adults with obesity or overweight, with a label expansion in March 2024 adding cardiovascular risk reduction indications
Research is in the early phases and it will take years to determine if the drugs effectively prevent cognitive decline
We will also share a semaglutide weight loss dosage chart that breaks this all down at a quick glance, so you can easily reference the dosing schedule
#TheLabDoc #TheLabDocSeries #LaboratoryMedicine #ClinicalBiochemistry #ClinicalChemistry #HbA1c #Diabetes #Anemia #ClinicalPathology #MedicalEducation #InterpretativeComments #ClinicalReasoning #PatientSafety #Diagnostics #EvidenceBasedMedicine #LaboratoryQuality #HealthcareInnovation #Endocrinology #Pathology #TeamBasedCare To view or add a comment, sign in The biggest wave of obesity clinical trials in history is building right now
When you lose muscle, youre diminishing one of your best tools for weight loss
